Adjuvant capecitabine in biliary tract cancer: a standard option?

Mené sur 447 patients atteints d'un cancer des voies biliaires ayant été réséqué, cet essai de phase III évalue l'intérêt, du point de vue de la survie globale, et la toxicité de la capécitabine en traitement adjuvant par rapport à une surveillance active après le traitement chirurgical

Résumé en anglais

In The Lancet Oncology, John Primrose and colleagues have tackled the question of adjuvant treatment for a rare cancer: biliary tract cancer, an unresolved question to date. Although a meta-analysis (of mostly retrospective data) has suggested improved overall survival with adjuvant treatment (especially chemotherapy in patients with node-positive disease and adjuvant radiation-based therapy after R1 resection), older randomised studies were not sufficiently statistically powered to define a standard of care, and two recent randomised studies did not show a significant benefit of gemcitabine or gemcitabine plus oxaliplatin (GEMOX regimen).